Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4-6 inhibitors?

Autor: Gültürk I; Istanbul Research and Training Hospital, Department of Medical Oncology, Istanbul, Turkey. Electronic address: gulturkilkay@gmail.com., Colak R; Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Department of Medical Oncology, Istanbul, Turkey., Kapar C; Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Department of Medical Oncology, Istanbul, Turkey., Guliyev M; Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Oncology, Istanbul, Turkey., Yıldırım C; Istanbul Research and Training Hospital, Department of Medical Oncology, Istanbul, Turkey., Yilmaz M; Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Department of Medical Oncology, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Breast (Edinburgh, Scotland) [Breast] 2024 Dec; Vol. 78, pp. 103820. Date of Electronic Publication: 2024 Oct 10.
DOI: 10.1016/j.breast.2024.103820
Abstrakt: Introduction: Cyclin Dependent Kinase (CDK) 4-6 inhibitors are the recommended first-line treatment option for hormone-positive metastatic breast cancer (MBC). They show their effects by causing cell cycle arrest in G1-S phase. Neutropenia is the most common haematological side effect. In the literature, data on the association between CDK 4-6 inhibitors and macrocytosis are limited. We aimed to investigate the effect of macrocytosis on survival.
Methods: We retrospectively analysed 133 patients with de novo hormone positive MBC using CDK 4-6 inhibitors in first line treatment. Mean Corpuscular Volume (MCV) > 100 was considered macrocytosis and patients were divided into two groups; MCV<100 and MCV >100. The association of macrocytosis with clinicopathological features, Progression Free Survival (PFS) and Overall Survival (OS) were evaluated.
Results: 42 patients were receiving palbociclib and 81 patients were receiving ribociclib. Median OS was determined as 33 months and median PFS was determined as 22 months. Macrocytosis ever rate was 45.8 % during follow-up. Macrocytosis was observed in 4.2 % of the patients in the first month, 16.7 % in the third month, 41.6 % in the sixth month and 42.2 % in the twelfth month. ER receptor level, ki-67, macrocytosis at 6-12 months and macrocytosis-ever which were found to affect OS as a result of univariate Cox regression analysis, were evaluated with multivariate Cox regression models and it was observed that they had significant effect on PFS and OS.
Conclusion: Macrocytosis may be a useful biomarker for the prediction of PFS and OS in MBC patients receiving CDK 4-6 inhibitors.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: